We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+11.87%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$370M
AUM Growth
+$73.9M
(+25%)
Cap. Flow
+$48.9M
Cap. Flow
% of AUM
13.23%
Top 10 Holdings %
Top 10 Hldgs %
99.21%
Holding
14
New
1
Increased
6
Reduced
5
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$56.7M |
| 2 |
Elanco Animal Health
ELAN
|
+$21.6M |
| 3 |
Amgen
AMGN
|
+$2.92M |
| 4 |
Gilead Sciences
GILD
|
+$1.87M |
| 5 |
United Therapeutics
UTHR
|
+$1.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$24.4M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
+$5.27M |
| 3 |
Orthofix Medical
OFIX
|
+$2.97M |
| 4 |
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
|
+$2.28M |
| 5 |
Merck
MRK
|
+$1.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$25.8B
| $59.3M | 16.03% |
505,299
+13,606
| +3% | +$1.59M |
|
2
McKesson
MCK
$100B
| $48.2M | 13.02% |
411,655
+4,165
| +1% | +$514K |
|
|
3
Enanta Pharmaceuticals
ENTA
$366M
| $45.5M | 12.29% |
476,042
-58,783
| -11% | -$5.27M |
|
|
4
Biogen
BIIB
$30B
| $42.5M | 11.5% |
+180,000
| New | +$56.7M |
|
|
5
Amgen
AMGN
$208B
| $36.8M | 9.94% |
193,670
+15,312
| +9% | +$2.92M |
|
|
6
Gilead Sciences
GILD
$162B
| $36.3M | 9.82% |
558,827
+28,128
| +5% | +$1.87M |
|
|
7
Merck
MRK
$322B
| $34.3M | 9.28% |
432,624
-18,139
| -4% | -$1.36M |
|
|
8
Elanco Animal Health
ELAN
$13.2B
| $29M | 7.84% |
904,202
+703,235
| +350% | +$21.6M |
|
|
SRGA
9
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $23.9M | 6.45% |
132,400
-15,726
| -11% | -$2.28M |
|
|
IVC
10
DELISTED
Invacare Corporation
IVC
| $11.3M | 3.05% |
1,349,741
+19,842
| +1% | +$143K |
|
|
AVNS
11
DELISTED
Avanos Medical
AVNS
| $2.65M | 0.72% |
62,057
-2,458
| -4% | -$110K |
|
|
STRR
12
DELISTED
Star Equity Holdings
STRR
| $269K | 0.07% |
5,903
-694
| -11% | -$26.6K |
|
|
13
Orthofix Medical
OFIX
$477M
| – | – |
-56,664
| Closed | -$2.97M |
|
|
SHPG
14
DELISTED
Shire pic
SHPG
| – | – |
-140,157
| Closed | -$24.4M |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q1 2019 Portfolio in Review
As of Q1 2019, Krensavage Asset Management held 14 positions worth $370M, up 25% from $296M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Krensavage Asset Management deployed $48.9M of net new capital in Q1 2019, opening 1 new position and adding to 6 existing holdings. Its largest new stake was Biogen: 180,000 shares worth $42.5M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.
On the sell side, the largest reduction was Enanta Pharmaceuticals, an estimated $5.27M trimmed.
- Krensavage Asset Management's largest Q1 2019 buy was Biogen: 180,000 shares worth $42.5M.
- Krensavage Asset Management added most to Elanco Animal Health in Q1 2019, an estimated $21.6M increase.
- Krensavage Asset Management's biggest Q1 2019 reduction was Enanta Pharmaceuticals, cutting an estimated $5.27M.
- Krensavage Asset Management fully exited Shire pic in Q1 2019, selling an estimated $24.4M.
- Krensavage Asset Management's ten largest holdings make up 99% of its $370M portfolio in Q1 2019.
- Krensavage Asset Management opened 1 new position and closed 2 in Q1 2019.
- Krensavage Asset Management's portfolio value rose 25% quarter-over-quarter to $370M.
Based on Krensavage Asset Management's 13F filing for Q1 2019, filed 15 May 2019.